bromhexine - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical deterioration 0.48 [0.01, 27.44]< 10%1 study (1/-)63.7 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %some concernnot evaluable moderateimportant-
hospital discharge 10.00 [1.03, 97.50]> 10%1 study (1/-)97.5 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.40 [0.04, 3.90]< 10%1 study (1/-)78.3 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.00 [0.03, 34.67]> 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-

safety endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.